Footnote: per this abstract from the Journal of Cl
Post# of 148110
https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.e13062
The murine glioblastoma study at Montefiore will obviously be of great interest. I have a recollection from that Leronlimab has demonstrated 70% CCR5 receptor occupancy in the brain, so we can infer it does cross the blood brain barrier. Knowing the central role this receptor plays in some cancers (VEG-F inhibitor etc…) I am optimistic but we will have to wait till this plays out in a clinical trial…the mice will have the first word.